Summary
Eli Lilly and Company reported a significant increase in revenue for the second quarter and the first six months of 2018 compared to the prior year, driven by strong volume and favorable foreign exchange rates. However, the company posted a net loss of $259.9 million for the quarter, a stark contrast to the $1.008 billion net income in the same period last year. This loss was heavily influenced by a substantial $1.62 billion charge related to acquired in-process research and development (IPR&D) for acquisitions like ARMO Biosciences and AurKa Pharma, as well as a collaboration with Sigilon Therapeutics. Despite the quarterly loss, the first six months of the year remained profitable with $957.5 million in net income. Key developments include significant investments in late-stage pipeline assets and ongoing strategic review of the Elanco animal health business, with plans for a potential IPO. The company also faces ongoing patent litigation, particularly concerning Alimta, which could materially impact future results. Investors should note the substantial R&D investment and the impact of acquisitions on the current quarter's profitability, while revenue growth trends remain positive.
Financial Highlights
53 data points| Revenue | $5.58B |
| Cost of Revenue | $1.23B |
| Gross Profit | $4.35B |
| R&D Expenses | $1.27B |
| SG&A Expenses | $1.49B |
| Operating Expenses | $2.76B |
| Interest Expense | $63.30M |
| Net Income | -$259.90M |
| EPS (Basic) | $-0.25 |
| EPS (Diluted) | $-0.25 |
| Shares Outstanding (Basic) | 1.03B |
| Shares Outstanding (Diluted) | 1.03B |
Key Highlights
- 1Revenue increased by 9% for both the three and six months ended June 30, 2018, compared to the prior year, driven by volume and favorable foreign exchange rates.
- 2The company reported a net loss of $259.9 million for the three months ended June 30, 2018, primarily due to $1.62 billion in acquired IPR&D charges from acquisitions of ARMO Biosciences, AurKa Pharma, and collaboration with Sigilon Therapeutics.
- 3Net income for the six months ended June 30, 2018, was $957.5 million, an increase from $897.2 million in the same period last year.
- 4Significant investments were made in the late-stage pipeline, with several New Molecular Entities (NMEs) in Phase III trials or submitted for regulatory review.
- 5Eli Lilly is undergoing a strategic review of its Elanco animal health business, with plans for a potential Initial Public Offering (IPO) in the second half of 2018.
- 6The company continues to face patent litigation, notably for Alimta, with potential for material adverse effects on future results.
- 7Diluted Earnings Per Share (EPS) was $(0.25) for the quarter, compared to $0.95 in the prior year's quarter, largely due to IPR&D charges.